Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda StudyMichael Bishop, Jason R. Westin, Duncan Purtill et al.|Blood|2021Cited by 15